Preleukemia

This is an early stage of leukemia, a type of cancer affecting blood cells. It means there are abnormal changes in the blood or bone marrow, but they aren't severe enough to be diagnosed as leukemia yet. It's considered a precursor to leukemia.

Condition

What people with Preleukemia report

Every report comes from a Lived member, sent anonymously.

Have you had Red Blood Cell Transfusion for Preleukemia?

NameHow it went

About Preleukemia

What It Is

Preleukemia is an older name for a group of bone marrow conditions now called myelodysplastic syndromes (MDS). In MDS, some of the stem cells in the bone marrow that make blood become abnormal. They produce blood cells that are defective or die early, so the body runs short of healthy red blood cells, white blood cells, platelets or a combination of them. Those shortages explain most of what people experience: tiredness and shortness of breath from anemia, more frequent or serious infections, and easy bruising or bleeding. The old name reflected the observation that these conditions can turn into leukemia. Doctors no longer think of MDS as a mere warning stage: it is now classified as a form of cancer in its own right. About 1 in 3 people with MDS go on to develop acute myeloid leukemia (AML), a fast-growing cancer of the bone marrow, while many others live with lower-risk MDS for years. The idea of a stage before leukemia has also taken a newer form. Genetic testing of blood sometimes finds a mutation in a small population of blood cells in people who have normal or mildly low blood counts. This is called clonal hematopoiesis. When blood counts are normal it is known as clonal hematopoiesis of indeterminate potential (CHIP); when counts are low without another explanation it is clonal cytopenia of undetermined significance (CCUS). It becomes more common with age, it is not MDS, and most people who have it never develop a blood cancer.

Causes & Risk Factors

In most people with MDS, no specific cause is found. The condition starts with genetic changes that build up in blood-forming cells over a lifetime, which is why age is the strongest risk factor. MDS can occur at any age, but it is uncommon before 50 and most often diagnosed in people in their 70s or 80s. It is somewhat more common in men. A minority of cases are linked to an identifiable exposure. Earlier chemotherapy or radiation therapy for another cancer can lead to what is called treatment-related or secondary MDS, although only a small share of people who receive those treatments develop it. Smoking, long-term workplace exposure to benzene and some chemicals used in the petroleum, rubber and agricultural industries, and very high radiation exposure also raise the risk. In children and some families, MDS is tied to inherited conditions such as Fanconi anemia, Down syndrome or inherited platelet and bone marrow disorders. Having a risk factor does not mean someone will develop MDS, and many people who do have no known risk factor.

How It's Diagnosed

MDS is often first suspected when a routine blood test shows a low blood count that has no obvious cause. A complete blood count (CBC) measures red cells, white cells and platelets, and a specialist looks at a blood smear under a microscope for abnormally shaped cells. Because low counts have many common explanations, the workup also measures substances such as vitamin B12 and folate, because shortages of them and other conditions can mimic MDS. A bone marrow aspiration and biopsy is usually needed to confirm the diagnosis. After the skin is numbed, a hollow needle is passed into the hip bone (occasionally the breastbone) to remove a small sample of marrow and bone. The sample shows how many immature cells, called blasts, are present and whether developing cells look abnormal. Tests on the same sample look for chromosome changes and gene mutations. These results go into a scoring system, most often the Revised International Prognostic Scoring System (IPSS-R) or its newer molecular version (IPSS-M), which adds gene results. They combine the blast percentage, chromosome or gene findings and blood counts to place someone in a lower-risk or higher-risk group. The risk group is one of the most important results, because it estimates how likely MDS is to progress and guides treatment, although it cannot predict any one person's course with certainty.

Treatment Options

Treatment depends mainly on the risk group, the symptoms low blood counts are causing, and a person's age, overall health and preferences. Some people with lower-risk MDS and no troublesome symptoms are monitored with regular checkups and blood counts rather than treated right away, sometimes for many years. It is not clear that early treatment helps these people live longer, and it can cause side effects. When anemia or other low counts start to cause problems, the focus is on raising counts and reducing symptoms. Red blood cell and platelet transfusions are common. People who need many transfusions over years can build up excess iron in the liver and heart, so iron levels are tracked, iron supplements are usually avoided, and iron-removing medicines (chelation) may be used. Injections of red cell growth factors can reduce how often transfusions are needed for some people, and luspatercept (Reblozyl) helps the marrow produce more mature red cells. For MDS with a specific chromosome change called del(5q), lenalidomide (Revlimid), an oral medicine that acts on the immune system and abnormal cells, often reduces or eliminates the need for transfusions. Higher-risk MDS usually needs treatment promptly. Azacitidine and decitabine, called hypomethylating agents, are lower-intensity chemotherapy drugs that act on the abnormal cells and can slow progression to AML. They are given in repeated treatment cycles, and decitabine is also available as a tablet combined with cedazuridine (Inqovi). They control the disease rather than cure it. A stem cell transplant from a donor is the only treatment that offers a chance of long-term remission or cure. It replaces the diseased marrow after chemotherapy, but it is intensive and carries serious risks, so it suits only people strong enough to tolerate it who have a suitable donor. Because many questions about the best treatment remain open, clinical trials are a reasonable option at several points. Clonal hematopoiesis (CHIP or CCUS) has no approved treatment. Care centers on periodic blood counts and attention to heart health, since CHIP is also linked to a higher risk of cardiovascular disease.

What to Expect

The course of MDS varies more than the word leukemia might suggest. Some people with lower-risk disease feel well and need only periodic blood tests for years. Others need regular transfusions or injections, which shape daily life through frequent clinic visits and fatigue that comes and goes with blood counts. Higher-risk MDS tends to move faster, and treatment decisions, including whether a transplant makes sense, usually come early. Ongoing follow-up matters at every stage. Blood counts are checked regularly, and a repeat bone marrow test may be done if counts change, because MDS can shift to a higher-risk form or progress to AML. If one treatment stops working, others may still help. Low white cell counts make infections more likely and more serious, so staying current with vaccines, caring for cuts promptly and knowing the care team's plan for fever become part of routine life. For people found to have CHIP or CCUS, the usual experience is monitoring rather than treatment. The risk of progression varies widely with the specific mutation and blood counts, and specialists can estimate it more precisely for each person.

When to Seek Help

See a clinician if you have ongoing tiredness, weakness, breathlessness with ordinary activity or paler skin than usual, or if a blood test shows a low count that has not been explained. If you already have MDS, mention new or worsening symptoms at your next visit rather than waiting for them to settle. Call your care team right away for a fever, chills, a new cough, burning when urinating or other signs of infection, especially if your white cell count is low, and follow any fever instructions your team has given you. Contact them promptly as well for frequent or severe nosebleeds, bleeding gums, unusual bruising or tiny purple spots on the skin, which can signal a falling platelet count.

Questions to Ask Your Doctor

  1. 1.Is my diagnosis MDS, clonal hematopoiesis or something else, and what did the bone marrow and genetic tests show?
  2. 2.What is my risk group, and what does it mean for how likely my condition is to progress?
  3. 3.Do I need treatment now, or is monitoring reasonable, and what changes would prompt us to start?
  4. 4.Am I a possible candidate for a stem cell transplant, and should we start looking for a donor?
  5. 5.What should I do if I get a fever or start bleeding, and whom should I call after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.